ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results. Here are details of ImmuONE‘s latest funding round :
🚀 Launch
2019
🏭 Industry
Biotechnology
🧠Management
DR ABIGAIL MARTIN (CEO CO-FOUNDER), DR VICTORIA HUTTER (CSO CO-FOUNDER), DR EWELINA HOFFMAN (PRINCIPAL LEAD SCIENTIST)
💸 Funding & Investors
| INVESTMENT (October 2023) | £2 million |
| INVESTORS (October 2023) | led by MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF). |
🎯 Funding purpose
Move into new headquarters in Milton Keynes, new laboratories in Stevenage to meet the growing demand and additionally expand capacity, continue its research and development, grow its team and create six new jobs.
🌐 Country HQ
UK (Hatfield)